Inspira Technologies Oxy B.H.N. Ltd. Warrant - IINNW STOCK NEWS

Welcome to our dedicated page for Inspira Technologies Oxy B.H.N. Ltd. Warrant news (Ticker: IINNW), a resource for investors and traders seeking the latest updates and insights on Inspira Technologies Oxy B.H.N. Ltd. Warrant stock.

Inspira Technologies Oxy BHN Ltd is a specialty medical device company focused on developing innovative respiratory support technology as an alternative to mechanical ventilation. By 2020, over 600,000 patients in the U.S. will need mechanical ventilation, with a significant portion requiring ICU admission, costing an estimated $64 billion annually. The company's OxyLink technology, an advanced nano vesicle device, introduces an intravascular oxygenation system to enhance blood oxygen levels and reduce carbon dioxide, enabling physicians to address primary ventilatory conditions effectively.

The company has recently received 510(k) class II clearance from the U.S. FDA for its INSPIRA ART100 Cardiopulmonary Bypass System. Inspira Technologies aims to revolutionize the respiratory care market with its innovative products, including the INSPIRA ART (Gen 2) system designed to elevate patient oxygen levels and potentially reduce the need for mechanical ventilation, providing new treatment alternatives and enhancing patient care.

11/16/2023 09:40 AM

News

Inspira™ Technologies Reports Third Quarter 2023 Financial Results

Rhea-AI Summary

Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) Announces Q3 Financial Results and Progress in Novel Oxygenation Technology Development

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-2%

Tags

11/06/2023 09:02 AM

News

Inspira™ Announces Israeli Innovation Authority Grant for New VORTX™ Disposable Blood Oxygenation Technology

Rhea-AI Summary

Inspira Technologies has received a grant from the Israeli Innovation Authority for its VORTX Disposable Blood Oxygenation Technology. The VORTX is designed to oxygenate blood and remove carbon dioxide, addressing a $4 billion perfusion disposable market in the medical devices sector. The grant covers 40% of the first-year approved budget of $1 million.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-0.79%

Tags

10/25/2023 08:30 AM

News

Inspira™ Granted U.S. Patent for INSPIRA™ ART500 Medical Device

Rhea-AI Summary

Inspira Technologies receives additional patent for respiratory medical device, INSPIRA ART500

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

1.63%

Tags

10/24/2023 08:30 AM

News

Inspira™ Terminates ATM Program and Provides an Update

Rhea-AI Summary

Inspira Technologies terminates its at-the-market equity offering program. Operations unaffected by ongoing war.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-3.15%

Tags

10/10/2023 09:30 AM

News

Inspira™ Enters into a Distribution Agreement in Central America with CIO MED GROUP

Rhea-AI Summary

Inspira Technologies signs distribution agreement with CIO MED GROUP, potentially generating $28 million in recurring revenues

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

1.61%

Tags

09/28/2023 08:30 AM

News

Inspira™ Technologies Unveils the INSPIRA™ ART Line of Medical Devices at the World's Largest Extracorporeal Life Support Conference

Rhea-AI Summary

Inspira Technologies unveils INSPIRA ART line at ELSO Conference, including INSPIRA ART100 and ART500 devices. INSPIRA ART500 offers potential breakthrough treatment for severe breathing problems. INSPIRA ART100 estimated to receive FDA clearance in H1 2024. Collaboration with Perfusion Solution for U.S. availability.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

6.15%

Tags

09/13/2023 08:30 AM

News

Inspira™ Announces 510(k) FDA Submission of INSPIRA™ ART100 Towards Commercialization

Rhea-AI Summary

Inspira Technologies submits INSPIRA ART 100 to FDA, expects clearance in first half of 2024

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

8.82%

Tags

08/10/2023 09:00 AM

News

Inspira™ Technologies Reports Second Quarter 2023 Financial Results

Rhea-AI Summary

Inspira Technologies OXY B.H.N. Ltd. announces financial results for Q2 2023. The company had $8.9 million in cash, cash equivalents, and short-term bank deposits as of June 30, 2023. The INSPIRA ART100 is planned for submission to the FDA for clearance. The INSPIRA ART500 is being developed with integrated AI and blood sensor technology. The net loss for the six months ended June 30, 2023, was $5.9 million.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

5.6%

Tags

08/09/2023 08:30 AM

News

INSPIRA™ ART100 Completes Usability Study in Boston Massachusetts, U.S.

Rhea-AI Summary

Inspira Technologies completes Usability Study for INSPIRA ART100 device

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-1.97%

Tags

07/24/2023 09:17 AM

News

Inspira™ Technologies Receives Certification of Medical Devices Quality Management Systems, Another Step Towards EU Regulatory Approval

Rhea-AI Summary

Inspira Technologies has received ISO 13485:2016 Standard Certification, a requirement for EU regulatory approval. The certification demonstrates adherence to the highest quality management standards in the medical device industry.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

3.47%

Tags

FAQ

What is the current stock price of Inspira Technologies Oxy B.H.N. Ltd. Warrant (IINNW)?

The current stock price of Inspira Technologies Oxy B.H.N. Ltd. Warrant (IINNW) is $0.38 as of November 1, 2024.

What is Inspira Technologies Oxy BHN Ltd known for?

Inspira Technologies specializes in developing respiratory support technology as an alternative to mechanical ventilation.

What is the significance of OxyLink technology?

OxyLink is an advanced intravascular oxygenation apparatus that enhances blood oxygen levels and reduces carbon dioxide, facilitating effective treatment of ventilatory conditions.

What recent FDA clearance has Inspira Technologies received?

Inspira Technologies has received 510(k) class II clearance from the U.S. FDA for its INSPIRA ART100 Cardiopulmonary Bypass System.

How does the INSPIRA ART (Gen 2) system aim to revolutionize patient care?

The INSPIRA ART (Gen 2) system is designed to elevate patient oxygen levels, potentially reducing the need for mechanical ventilation and offering new treatment alternatives.

What is the core mission of Inspira Technologies?

Inspira Technologies aims to enhance patient care by developing innovative medical technologies that address critical respiratory needs and revolutionize the life support arena.